Oncolytics Biotech : What does our poster mean? Combination Carfilzomib and the Viral Oncolytic Agent Reolysin in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation

Preliminary correlative studies indicated a higher degree of viral RNA, capsid protein, and cell death following REOLYSIN + Carfilzomib® treatment, compared to REOLYSIN alone. Additionally, REOLYSIN + Carfilzomib® treatment was associated with upregulation of PD-L1 on abnormally growing plasma cells (high expression of PD-L1 is associated with increased tumor aggressiveness) and increased infiltration of cancer-killing T cells.

These interesting findings necessitate continued investigation, and suggest that the addition of a PD1/PDL1 inhibitor may further optimize the REOLYSIN + Carfilzomib® treatment regimen.